Q-omics provides the consensus-scored AADACL3 profile across patient tissues and cancer cell-line models. AADACL3 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, AADACL3 is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, AADACL3 RNA expression shows 6,403 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRP, BRCA, and STAD as cancer lineages where AADACL3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AADACL3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AADACL3 survival associations across molecular data types. AADACL3 RNA expression shows survival associations in the most cancer types (13), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AADACL3 RNA expression–survival associations across cancer types. High AADACL3 expression shows unfavorable associations in KIRP, THCA, PCPG, PAAD and ACC, but favorable associations in MESO. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for AADACL3 RNA expression.
This table summarizes AADACL3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for AADACL3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AADACL3 shows lower tumor expression in BRCA and KIRC and higher tumor expression in HNSC. The BRCA box plot shows higher AADACL3 RNA expression in normal versus tumor tissue (log2 FC = −0.170, t-test p < 0.001).
This table shows molecular features associated with AADACL3 in patient tissues and cancer cell lines. In patient samples, AADACL3 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, AADACL3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BONE.
